Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Articles|January 10, 2022
Rheumatoid Arthritis Quiz: Managing Early Rheumatoid Arthritis
Author(s)Ingrid Torjesen
Early diagnosis and prompt effective management are important for the best outcomes in rheumatoid arthritis. Test your knowledge of how to achieve this with this quiz.
Advertisement
Is the following statement true or false?
The recommendations in the 2021 American College of American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis are subdivided according to the length of duration of the condition.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement